Supply hopes

Valneva and SE in talks to fund Scots vaccine plant


Grant plan: The Livingston plant of Valneva

Valneva, the French vaccines developer, is in advanced talks with Scottish Enterprise to fund completion of its manufacturing site in Livingston which may produce Covid vaccines for Scotland.

The company put its plans on hold following the UK Government’s decision to cancel a £1.3bn order for Valneva’s COVID-19 vaccine candidate VLA2001. It claimed the company was in breach of contract.

Last month Daily Business revealed behind the scenes moves to reinstate the contract.

Today Valneva confirmed it is continuing to seek an amicable resolution with the UK Government and reserves all rights in the event that it does not.

Valneva and Scottish Enterprise have since engaged in a “highly constructive dialogue”, and under the proposed grant, the Livingston site will be fully developed as a key vaccine production site for the long term.

Both Valneva and Scottish Enterprise would invest in the plant. Scottish Enterprise’s contribution is expected to be through a series of grants totalling £10-20 million to enable Valneva to commence production at the plant.

Discussions between the Company and the Scottish Government also include potential supply of VLA2001 for Scotland in the future, subject to regulatory approval.

Valneva has also offered to make up to 25,000 doses of VLA2001 available for primary immunisation, free of charge, to National Health Service and frontline workers in Scotland, subject to regulatory approval.

The grant is subject to contract and final due diligence and is expected to include commitments to jobs for the future in Livingston.

Leave a Reply

Your email address will not be published. Required fields are marked as *

This site uses Akismet to reduce spam. Learn how your comment data is processed.